Wolverine Legal Status, FDA 503A Category, and Compounding Access

Access is under active FDA review — and may expand in 2026

The most important thing about the Wolverine legal status right now is that it is in motion. Both peptides in the BPC-157 TB-500 blend are on the published agenda of an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[14]. Compounding access to these peptides is being actively evaluated, and it may expand in 2026.

That momentum is real, and it is also bounded by a hard line: a scheduled PCAC discussion is a step in evaluation, not a listing decision. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee — being on the agenda is not the same as being listed ^[15]. No reclassification has occurred, none is dated, and the outcome of the July 2026 meeting is unknown. This page states what is scheduled, not what is decided.

So the forward-leaning reading is the honest one: access is under active review and could open. The present-tense fact underneath that review is what the next section states plainly.

The current FDA fact: Category 2, since September 29, 2023

As of today, both constituents of the Wolverine blend sit in FDA's 503A "Category 2" — bulk drug substances that FDA identified as potentially presenting significant safety risks. That placement is effective with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A ^[13].

Under FDA's interim policy, Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1; FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[15]. In practical terms, compounding-pharmacy access to these peptides is currently restricted while that status stands. FDA's cited safety rationale for these entries includes potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[13].

Neither peptide is an FDA-approved drug, and the blend has no approved therapeutic indication. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding — and on both questions, the answer for BPC-157 TB-500 today is that it is neither approved nor eligible for routine 503A compounding ^[15].

What is the FDA 503A status of Wolverine?

The blend is not an approved medicine. Both constituents are in FDA's Category 2 for 503A compounding, effective the September 29, 2023 list update ^[13], which means neither is currently eligible for routine 503A compounding while that status stands ^[15]. Both are also on the July 23-24, 2026 PCAC agenda as candidates under evaluation ^[14] — a scheduled discussion, not a decision.

Both components are on the July 2026 review — no carve-out

There is no component carve-out in the Wolverine blend. Both peptides are currently Category 2, and both are under the same one scheduled review.

FDA lists BPC-157 — evaluated as the entries "BPC-157 (free base)" and "BPC-157 acetate" — as a Category 2 bulk drug substance effective September 29, 2023 ^[13], and it appears on the July 23-24, 2026 PCAC agenda as a substance being considered for inclusion on the 503A Bulks List ^[14].

TB-500 is listed by FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — FDA's own entry establishes that TB-500 is the LKKTETQ fragment of thymosin beta-4. It is likewise a Category 2 bulk drug substance effective September 29, 2023 ^[13], and "TB-500 (free base)" / "TB-500 acetate" appear on the same July 23-24, 2026 PCAC agenda ^[14].

So both halves of the blend — the BPC-157 pentadecapeptide and the TB-500 Ac-LKKTETQ thymosin beta-4 fragment — are Category 2 today and are being considered together in the one scheduled July 2026 evaluation. Whatever the blend's status becomes, it moves as two peptides under one review, not as a carve-out for either.

How legally compounded peptide access works

Setting the specific peptides aside, this is the general shape of lawful compounded-medication access in the U.S. — described as information, not as a route to obtain any restricted substance.

A legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[15]. Telehealth can serve as the front-end channel for that prescriber evaluation, but it does not change which substances are eligible to be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[15].

The prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility ^[15]. The decisive caveat is ingredient eligibility: a compounder may use a bulk active ingredient only if it is permitted under the 503A/503B framework — covered by a USP/NF monograph, a component of an approved drug, or on the applicable FDA bulks list. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[15]. For the two peptides in this blend, that eligibility caveat is exactly the open question the July 2026 review concerns ^[14].

Can you get BPC-157 from a compounding pharmacy?

Under current FDA status, BPC-157 is a Category 2 bulk drug substance (effective September 29, 2023) and is therefore not eligible for routine 503A compounding while that status stands ^[13][15]. It is on the July 23-24, 2026 PCAC agenda as a candidate under evaluation ^[14] — scheduled for discussion, not yet listed. This is general regulatory information, not medical or legal advice and not a route to obtain any substance.

WADA and the safety record

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is approved by the FDA for human use ^[13], and both are prohibited by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 under prohibited peptide and tissue-repair categories ^[16]. The blend has no approved therapeutic indication and is banned in and out of competition for the relevant classes.

Is Wolverine legal?

Neither constituent is an approved drug, and the blend has no approved therapeutic indication. Both peptides are in FDA's Category 2 for 503A compounding ^[13], are sold by research suppliers for laboratory use only, and are WADA-prohibited ^[16]. "Legal" depends entirely on context — research-use supply, compounding eligibility, and anti-doping rules are separate questions, and the blend sits on the restricted side of each.

What are the side effects of BPC-157 and TB-500?

Human safety data are scarce. A 2025 BPC-157 systematic review found "no clinical safety data" ^[6], and recent reviews note potential for serious harm from unapproved peptides used outside regulatory oversight ^[7]. A theoretical tumor/angiogenesis concern attaches to the pro-migratory, pro-angiogenic properties shared by both peptides — a mechanistic consideration, not a demonstrated human outcome ^[4].

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, and the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a concern that compounds when two pro-repair peptides are combined ^[4]. This is a mechanistic safety consideration, not a demonstrated human outcome. This page is general information, not medical advice.

FDA's own pages are the authority for the regulatory facts above; the WADA Prohibited List is the authority for the anti-doping status. Nothing here is medical or legal advice, and nothing here is an offer to sell or supply any substance.